AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
AbbVie (NYSE: ABBV) and (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. With results like those, you might expect their stocks to still be soaring, but they aren't.
Instead, AbbVie and Pfizer shares have dropped by double-digit percentages this year, and for reasons that are understandable. The companies have something in common. Sales of both of their top-selling products are on the decline in a big way. Humira has lost exclusivity, and demand for Pfizer's coronavirus vaccine is declining now that we have exited the health-crisis stage of the pandemic. But does this mean you should follow the crowd and sell shares of these companies?
Source Fool.com
Pfizer Inc. Aktie
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.